IB T101
Alternative Names: IB-T101; OTX CD70 CAR-TLatest Information Update: 26 Sep 2024
At a glance
- Originator Inceptor Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Renal cell carcinoma
Most Recent Events
- 05 Sep 2024 IB T101 is available for licensing as of 05 Sep 2024. https://inceptor.bio/contact-us/
- 05 Sep 2024 Inceptor Bio plans a clinical trial for Renal cell carcinoma in Q4/2024 (Inceptor Bio pipeline, September 2024)
- 31 Oct 2023 Preclinical trials in Renal cell carcinoma in USA (Parenteral)